Tyfo IV

Additional Details

Our range of Tyfo IV comprises Ofloxacin 200 mg for each 100 ml. Tyfo IV is backed by in-vitro activity against a gamut of gram +ve and gram -ve aerobic and anaerobic bacteria. Tyfo IV has been recommended by some organizations for the effective treatment of diseases.

The noteworthy recommendation includes:

    CDC & WHO for treating MDR-TB Only quinolone
    USFDA for treating pelvic inflammatory disease

Features:

    Extended antibacterial coverage against both-aerobes and anaerobes
    Excellent penetration into pleural fluid, macrophages

The medicine acts the best defense against:

    Gastro intestinal infection
    Typhoid
    Pancreatitis
    Multi drug resistant TB
    Sexually transmitted diseases
    Pelvic inflammatory disease
    Acute uncomplicated urethral and cervical gonorrhoea
    Nongonococcal urethritis and cervicitis
    Uncomplicated cystitis
    Mixed infections of the urethra and cervix
    Urinary tract infections